Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 5 000 UNITS IN SODIUM CHLORIDE 0 45 versus MAGNESIUM SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 5 000 UNITS IN SODIUM CHLORIDE 0 45 versus MAGNESIUM SULFATE.
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45% vs MAGNESIUM SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, causing a conformational change that accelerates the inhibition of thrombin and activated factor X (factor Xa). It also catalyzes the inhibition of other coagulation factors including XIIa, XIa, IXa, and VIIa.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
IV: Initial bolus 80 units/kg, then continuous infusion at 18 units/kg/hr, adjusted to aPTT 1.5-2.5 times control. Subcutaneous: 5,000 units every 8-12 hours.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
None Documented
None Documented
Mean terminal elimination half-life is 1-2 hours at therapeutic doses, but it is dose-dependent and can increase with higher doses. Clinical context: Anticoagulant effect persists longer than plasma levels due to irreversible binding to antithrombin III.
Terminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Primarily renal, with some hepatic metabolism and reticuloendothelial system clearance. Unchanged heparin is excreted in urine via glomerular filtration; high molecular weight fractions are cleared more rapidly than low molecular weight fractions.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Category A/B
Category C
Electrolyte
Electrolyte